A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

By Somlo G.   Martel C.   Lau S.   Frankel P.   Ruel C.   Gu L.   Hurria A.   Chung C.   Luu T.   Morgan R.   Leong L.   Koczywas M.   McNamara M.   Russell C.   Kane S.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 899-906

Springer Publishing Company

Access to resources Recommend Favorite

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

By Eiermann W.  

Annals of Oncology, Vol. 12, Iss. 12, 2001-12 ,pp. : 57-62

Springer Publishing Company

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

By Miles David   Baselga José   Amadori Dino   Sunpaweravong Patrapim   Semiglazov Vladimir   Knott Adam   Clark Emma   Ross Graham   Swain Sandra  

Breast Cancer Research and Treatment, Vol. 142, Iss. 1, 2013-11 ,pp. : 89-99

Springer Publishing Company

Access to resources Recommend Favorite

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

By Venturini M.   Bighin C.   Monfardini S.   Cappuzzo F.   Olmeo N.   Durando A.   Puglisi F.   Nicoletto O.   Lambiase A.   Mastro L.  

Breast Cancer Research and Treatment, Vol. 95, Iss. 1, 2006-01 ,pp. : 45-53

Springer Publishing Company

Access to resources Recommend Favorite